CEO Thomas K. Equels stated: "The results of AMP-518 support AIM's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue. Our analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback